Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesThe Impact of Involved Field Radiation Therapy for Patients Receiving High-Dose Chemotherapy Followed by Hematopoietic Progenitor Cell Transplant for the Treatment of Relapsed or Refractory Hodgkin Disease
American Journal of Clinical Oncology, 04/07/06
Conclusions: Although the current study did not demonstrate an improvement in PFS with the addition of IFRT to HDCT and HPCT, there was a trend toward improved overall survival. The potential benefit of IFRT may be underestimated because of the heterogeneity of the treatment groups. The use of IFRT was not associated with an increase in the risk of acute mortality or late events
| Previous Article | Next Article |
Today in BMT/SCT...keeping you current
Receive free subspecialty "5-minute updates" via email
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia
British Journal of Haematology, 06/08/09
Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia
Medical Oncology, 06/05/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Neoadjuvant chemotherapy for locally advanced breast cancer: a single center experience
Medical Oncology, 06/05/09
American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
Journal of Clinical Oncology, 07/01/09
nab-paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial
Breast Cancer Research and Treatment, 06/09/09
Sponsor
Article Search
Sponsor